Anticancer metallodrug research analytically painting the "omics" picture--current developments and future trends.
Anticancer metallodrug development has for a long time been characterised by the similarity of new drug candidates to cisplatin and DNA as the primary target. Recent advances in bioanalytical techniques with high sensitivity and selectivity have revealed that metal-based drugs can undergo a wide range of biomolecular interactions beyond DNA and have generated interest in proteins as possible targets for metallodrugs. In fact, implementation of metallomics approaches that are able to reveal the fate of the compounds in biological systems can help to move drug development towards more targeted and rational design of novel metallodrugs. Additionally, proteomic screening and gene expression analysis can provide insight into physiological response to drug treatment and identify the reasons for drug resistance. Herein, we review selected applications which led to a better understanding of the mode of action of clinically established metal-based anticancer agents and novel metallodrug candidates.
Institute of Analytical Chemistry, University of Vienna, Waehringer Str. 42, 1090 Vienna, Austria. michael.groessl@univie.ac.at
Michael
M
Groessl
Christian G
CG
Hartinger
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D002623:Chemistry Techniques, Analytical; D002945:Cisplatin / Q000737:chemistry / Q000494:pharmacology; D004273:DNA, Neoplasm / Q000737:chemistry* / Q000378:metabolism; D015195:Drug Design; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D006801:Humans; D062105:Molecular Docking Simulation; D058990:Molecular Targeted Therapy; D009363:Neoplasm Proteins / Q000737:chemistry* / Q000378:metabolism; D009369:Neoplasms / Q000737:chemistry / Q000188:drug therapy / Q000378:metabolism; D009942:Organometallic Compounds / Q000138:chemical synthesis* / Q000494:pharmacology; D011485:Protein Binding; D040901:Proteomics / Q000295:instrumentation / Q000379:methods / Q000639:trends*
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D009363:Neoplasm Proteins; D009942:Organometallic Compounds; D002945:Cisplatin